Cover Image
市場調查報告書

Nociceptin受體:開發平台分析

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 358352
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
Nociceptin受體:開發平台分析 Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 59 Pages
簡介

本報告提供Nociceptin受體的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃相關資訊,以及最近的新聞和發表等訊息。

簡介

  • 調查範圍

Nociceptin受體概要

治療藥的開發

  • Nociceptin受體:開發中的產品 - 各開發階段
  • Nociceptin受體:開發中的產品 - 各治療範圍
  • Nociceptin受體開發中的產品 - 各適應症

Nociceptin受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Nociceptin受體:企業開發中的產品

Nociceptin受體:大學/機關開發中的產品

Nociceptin受體:治療藥的評估

  • 單劑療法/聯合治療產品的評估
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Nociceptin受體的治療藥開發企業

  • Astraea Therapeutics, LLC
  • F. Hoffmann-La Roche Ltd.
  • Grunenthal GmbH
  • Serodus ASA

Nociceptin受體的藥物簡介

Nociceptin受體:暫停中的計劃

Nociceptin受體:暫停中的計劃

Nociceptin受體:開發中止的產品

Nociceptin受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1104TDB

Summary:

According to the recently published report 'Nociceptin Receptor - Pipeline Review, H2 2017'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.

The report 'Nociceptin Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Immunology which include indications Neuropathic Pain, Dyskinesia, Inflammatory Pain, Substance (Drug) Abuse, Acute Pain, Chronic Pain, Pain, Alcohol Addiction, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, Post-Traumatic Stress Disorder (PTSD), Postherpetic Neuralgia, Pulmonary Arterial Hypertension, Systolic Hypertension and Visceral Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
  • The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Overview
    • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development
    • Blackthorn Therapeutics Inc
    • Fuso Pharmaceutical Industries Ltd
    • Grunenthal GmbH
    • Orexigen Therapeutics Inc
    • Serodus ASA
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles
    • AT-076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-089 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-326 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTRX-246040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cebranopadol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRT-6010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRTTA-2210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OREX-1038 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Agonize ORL1 for Acute Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-656570 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SER-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Products
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 24, 2017: BlackThorn Therapeutics Enrolls First Patient in Phase 2a Study of Lead Compound, BTRX-246040, in Major Depressive Disorder
      • Jul 10, 2017: Orexigen Announces Presentation of Preclinical Data for OREX-1038 at the International Narcotics Research Conference
      • Jan 05, 2017: Orexigen Therapeutics Provides Update on OREX-1038 at 35th Annual J.P. Morgan Healthcare Conference
      • Dec 19, 2016: Serodus: Novel article on SER100 in patients with isolated systolic hypertension is published in Journal of Clinical Pharmacology in Drug Development
      • Oct 25, 2016: Orphan drug designation for SER100 in Pulmonary Arterial Hypertension granted in U.S.
      • Sep 30, 2016: Grunenthal's cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain
      • Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder
      • May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile
      • Apr 18, 2016: PCT SER100 patent application filed - Serodus demonstrates a novel mechanism of action in Pulmonary Hypertension
      • Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
      • Apr 20, 2015: Provisional patent application filed for the Orphan Diseases of Pulmonary Hypertension
      • Sep 15, 2014: Serodus announces details on the clinical study of SER100 in patients with systolic hypertension
      • Sep 09, 2014: Serodus Announces Positive Phase IIa Clinical Study Results On SER100 In Patients with Systolic Hypertension
      • Jun 23, 2014: Serodus Completes The Enrollment Of Patients In Phase IIa Study
      • Nov 05, 2013: Serodus Enrolls First Patient in SER100 Phase IIa Isolated Systolic Hypertension Clinical Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Blackthorn Therapeutics Inc, H2 2017
  • Pipeline by Fuso Pharmaceutical Industries Ltd, H2 2017
  • Pipeline by Grunenthal GmbH, H2 2017
  • Pipeline by Orexigen Therapeutics Inc, H2 2017
  • Pipeline by Serodus ASA, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top